Anticipating When the FDA Will Treat Your Product as a Drug-Device Combination

January 17, 2018

Webinar

Jake M. Holdreith

Partner

Managing Partner, Minneapolis Office
Member of Executive Board

Oren D. Langer

Partner

Managing Partner, New York Office

The FDA considers a product a drug-device if it includes at least two of the following: a drug component, device component, or a biologic component. The FDA does not classify as a combination product, one that consists of similar components, e.g., drug-drug or device-device. However, bringing a combination device to market requires careful consideration of your strategy. During this session we will discuss the legal consequences of bringing your combination product to market from both a regulatory and patent litigation perspective.

Related Events

April 16, 2024
Trending Topics in Post Grant Reviews including IPRs
Cyrus Morton - MIPLA
Remote via Zoom
April 24, 2024
IP Leadership Executive Summit
Tom Hamlin, William Manske - IP Leadership Executive
San Jose, CA
April 24, 2024
IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
Jessica Gutierrez - FBA Minnesota Chapter
Minneapolis, MN
May 2-3, 2024
ACI Advanced Forum on Managed Care Disputes and Litigation
Nathaniel Moore - American Conference Institute
Chicago, IL